AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8819814
Drug: Propafenone 450‐900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 450‐900 mg/die
Trial: 2048373
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment control group (N = 4)
Trial: 22525561
Drug: Early endoscopic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early endoscopic treatment within 72 hours after initial symptom
Trial: 22525561
Drug: No endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endoscopic treatment (control group)
Trial: 20389025
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of insulin (0.1 IU/kg)
Trial: 7071350
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate (80 mg/kg)
Trial: 7071350
Drug: Intramuscular preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular preparation (AMPS: atropine, meperidine, promethazine, secobarbital)
Trial: 26203171
Drug: School-based drug-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based drug-treatment and health-education intervention
Trial: 17192324
Drug: Rosiglitazone (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (2-4 mg/day)
Trial: 17192324
Drug: Rosiglitazone (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (high-dose 8 mg/day)
Trial: 7846291
Drug: Psychotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic treatment alongside practical care, initiated during pregnancy and conducted in mothers' homes on a long-term basis.
Trial: 3044800
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment (induction scheme q 8 weeks)
Trial: 28328179
Drug: Delayed-release dimethyl
RxNorm normalized name: dimethyl fumarate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily
Trial: 28783872
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg)
Trial: 24029542
Drug: Warfarin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dosing algorithm with daily INR measurements
Trial: 19465443
Drug: IFNbeta‐1a 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a 30 microg IM once weekly
Trial: 19465443
Drug: IFNbeta‐1a 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily
Trial: 19465443
Drug: IFNbeta‐1a 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily plus prednisone 10 mg orally every other day
Trial: 11567748
Drug: Low-dose diphtheria-tetanus
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose diphtheria-tetanus vaccine (dT)
Trial: 11567748
Drug: Standard paediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard paediatric dose (DT)
Trial: 7843201
Drug: Single or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of natural porcine surfactant (Curosurf)
Trial: 7843201
Drug: Single-dose surfactant
RxNorm normalized name: surfactant protein-D homotrimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose surfactant treatment
Trial: 7843201
Drug: Multiple-dose surfactant
RxNorm normalized name: surfactant protein-D homotrimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose surfactant treatment
Trial: 28514945
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment performed
Trial: 23478662
Drug: Sildenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks)
Trial: 18315784
Drug: DTIC (2200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC (2200 mg/kg orally daily for 5 days, every 3 weeks)
Trial: 18315784
Drug: DTIC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC + CCNU (DTIC at 2200 mg/kg and CCNU at 120 mg/m2 once every 40 days)
Trial: 17023870
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate 1.25 mg
Trial: 17023870
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate 2.5 mg
Trial: 17023870
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate 5.0 mg
Trial: 17023870
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate 7.5 mg
Trial: 17023870
Drug: Increasing dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dose of methylphenidate
Trial: 9722817
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) with free treatment for 90 days
Trial: 9722817
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) without free treatment
Trial: 9722817
Drug: Risk reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk reduction (RR) with free treatment for 90 days
Trial: 9722817
Drug: Risk reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk reduction (RR) without free treatment
Trial: 7987510
Drug: Oral sumatriptan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan, 100 mg
Trial: 7987510
Drug: Subcutaneous sumatriptan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan, 6 mg
Trial: 7987510
Drug: Combined subcutaneous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined subcutaneous and oral administration of sumatriptan
Trial: 31340565
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% + 100 mg Tramadol (2 mL)
Trial: 31340565
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% + 2 mL NaCl 0.9% (placebo)
Trial: 18461664
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 108 individuals and 3365 students.
Trial: 18461664
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 3365 students.
Trial: 12135299
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (40,000 IU) administered preoperatively, with 2 or 3 doses depending on the procedure, along with oral iron for 14 or 21 days.
Trial: 9375348
Drug: Sequential exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential exercise day (SEB; at 1000, 1130, and 1300)
Trial: 9375348
Drug: Sequential exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential exercise day (SEB)
Trial: 7902470
Drug: H2-blockers (Histadyl)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2-blockers (Histadyl)
Trial: 7902470
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance therapy with drugs improving local microcirculation and stimulating bicarbonates production in gastric mucosa (synthetic prostaglandins analogues)
Trial: 30335135
Drug: Rotavac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavac vaccine (monovalent human-bovine 116E)
Trial: 29617381
Drug: PEG treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG treatment (both doses combined)
Trial: 25208561
Drug: Flavonoid-rich dark
RxNorm normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid-rich dark chocolate (50 g)
Trial: 25208561
Drug: Placebo chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo chocolate (50 g)
Trial: 21811866
Drug: Monthly ibandronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly ibandronate treatment for 12 months
Trial: 16911813
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Orlistat and Fenofibrate
Trial: 15951101
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg oral misoprostol every 4 h
Trial: 12030962
Drug: Alverine citrate
RxNorm normalized name: alverine citrate
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alverine citrate (120 mg capsule, three times daily for 12 weeks)
Trial: 7741779
Drug: Mexiletine-ratiopharm mite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine-ratiopharm mite (200 mg)
Trial: 7741779
Drug: Commercial reference
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial reference preparation
Trial: 25892165
Drug: Treatment manual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment manual (TM)
Trial: 23795737
Drug: Acetazolamide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (125 mg bid)
Trial: 23795737
Drug: Gingko biloba
RxNorm normalized name: Gingko Biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gingko biloba (120 mg bid)
Trial: 20153154
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing 200mg red yeast rice extract and 10mg policosanols once-daily for 8 weeks
Trial: 17704425
Drug: CRT‐IA (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT‐IA (150 mg/m², four courses) with sodium thiosulfate
Trial: 17704425
Drug: CRT‐IV (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT‐IV (100 mg/m², three courses) without sodium thiosulfate
Trial: 15073851
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and Paclitaxel (CP) - Paclitaxel at a dose of 225 mg/m² and carboplatin (AUC of 6) every 21 days
Trial: 15073851
Drug: Methotrexate, Vinblastine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) - standard dosage
Trial: 11560562
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) with ABC and ASA
Trial: 11560562
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) with T and ASA
Trial: 11560562
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (reviparin, REV) with ABC and ASA
Trial: 11560562
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (reviparin, REV) with T and ASA
Trial: 31710593
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage (15-min twice a day for 3 days)
Trial: 30987668
Drug: EPA and
RxNorm normalized name: Norwegian Cod Liver Oil With EPA and DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA and DHA supplementation (600 mg EPA and 260 mg DHA per day for 8 weeks)
Trial: 28389552
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg TCZ + MTX
Trial: 28389552
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg TCZ + MTX
Trial: 19785727
Drug: Financial incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial incentive for each anti-psychotic depot medication received over a 12 month period
Trial: 11499801
Drug: Inhibitor titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor titer < 2.0 U/mL
Trial: 11499801
Drug: Inhibitor titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor titer >= 2.0 U/mL
Trial: 31542384
Drug: Levoketoconazole, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levoketoconazole, starting at 150 mg twice daily, titrated up to a maximum of 600 mg twice daily during a 2-21 week dose-titration phase followed by a 6-month maintenance phase.
Trial: 31542384
Drug: Levoketoconazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levoketoconazole treatment
Trial: 26464000
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of dexmedetomidine (DEX) 0.8 μg · kg‐1 · min‐1
Trial: 19388120
Drug: Gadolinium doped
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium doped saline flush (50 mM gadolinium, total Gd: 0.11 mmol/kg, flow-rate: 2 mL/s)
Trial: 19388120
Drug: Pure saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure saline flush (0.9% saline solution)
Trial: 14983408
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + recombinant human growth hormone (rhGH) (daily dose 9.5 microg/kg body weight)
Trial: 25802471
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Placebo
Trial: 10450619
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) led by professional therapists
Trial: 10450619
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) led by paraprofessional therapists
Trial: 10450619
Drug: Mutual Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutual Support Group Therapy (MSG) led by professional therapists
Trial: 10450619
Drug: Mutual Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutual Support Group Therapy (MSG) led by paraprofessional therapists
Trial: 7570730
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (1 g/kg body wt)
Trial: 7570730
Drug: Oral xylose
RxNorm normalized name: Xylose
DrugBank: Xylose (DB09419)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral xylose (0.83 g/kg)
Trial: 732296
Drug: 4 pollen
RxNorm normalized name: POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 pollen extract capsules
Trial: 732296
Drug: 4 protein
RxNorm normalized name: ABCB4 protein, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 protein extract capsules
Trial: 732296
Drug: 4 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo capsules
Trial: 22027860
Drug: 12-week medicine
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week medicine ball training program
Trial: 11309322
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of TNF with 1.5 mg/kg melphalan
Trial: 11309322
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg melphalan alone
Trial: 1259120
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine administered 5 minutes before surgery to half of the patients (25 patients).
Trial: 1259120
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine without atropine (unatropinised group, 25 patients).
Trial: 22057076
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg intravenous, starting from the 3rd week of transplantation for 3 months)
Trial: 22057076
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg oral per week for 3 months)
Trial: 19735523
Drug: Daytime SPF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime SPF 30 lotion
Trial: 19735523
Drug: Night cream
RxNorm normalized name: Eucerin Q10 Anti-Wrinkle + Pro Retinol Night Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night cream
Trial: 19735523
Drug: Eye cream
RxNorm normalized name: EYE CREAM
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eye cream
Trial: 19735523
Drug: Wrinkle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrinkle treatment
Trial: 11308999
Drug: 8 ng.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ng. ml‐1 plasma remifentanil
Trial: 11308999
Drug: 4 ng.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ng. ml‐1 plasma remifentanil (Control)
Trial: 9920455
Drug: N‐nitro‐L‐arginine methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐nitro‐L‐arginine methyl ester (L‐NAME) 40 mg/kg injected plus 50 mg/kg infused over 60 min
Trial: 8049459
Drug: Initial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial therapy
Trial: 3393023
Drug: Intensive maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive maintenance therapy (chemotherapy: cytosine arabinoside plus 6-thioguanine, 100 mg/m2 every 12 hr for a variable number of days, repeated every three months for three or more years)
Trial: 3393023
Drug: Splenectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splenectomy plus chemotherapy (control group)
Trial: 3393023
Drug: Immunotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy plus chemotherapy (control group)
Trial: 29853416
Drug: Single Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Infusion (SI) - 0.2 mg kg−1 minute−1 for 240 minutes after a bolus of 2 mg kg–1
Trial: 29853416
Drug: 3-step Infusion
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-step Infusion - 0.4 mg kg−1 minute−1 for 10 minutes, then 0.3 mg kg−1 minute−1 for 30 minutes, and then 0.2 mg kg−1 minute−1 for 200 minutes after a bolus of 2 mg kg–1
Trial: 22004585
Drug: Oral EDTA-Na-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral EDTA-Na-Fe (60 mg Fe/dose, three times a week) and a 2-week course of colloidal bismuth subcitrate, amoxicillin and metronidazole
Trial: 18823410
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin intervention
Trial: 18823410
Drug: Placebo vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vs. active drug assignment
Trial: 12079930
Drug: Routine dose
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine dose of thyroxin administered orally or via nasogastric tube in the perioperative period, no supplemental dose used.
Trial: 9617439
Drug: Intracutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injection of vasoactive intestinal polypeptide (VIP) at concentrations of 1.5 x 10(‐7), 1.5 x 10(‐6), and 1.5 x 10(‐5) M; combined with acetylcholine (ACh) at 5.5 x 10(‐6) M.
Trial: 9617439
Drug: Intracutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injection of VIP and ACh
Trial: 9617439
Drug: ACh administration
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACh administration
Trial: 9161245
Drug: One-stage, nonsubmerged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage, nonsubmerged ITI implants
Trial: 11181673
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m(2) + cisplatin 75mg/m(2) + granulocyte colony-stimulating factor (Arm A)
Trial: 11181673
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg/m(2) + cisplatin 75 mg/m(2) (Arm B)
Trial: 9037637
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (3 micrograms/kg per min)
Trial: 3827416
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 10 mg administered sublingually